

Dedication

To the soul of my
parents,

Acknowledgement

This study was carried out in part. at Sudan University of science and technology, at Nacional Health Laboratorios (Metchan Lab) and most of the work at the Department of Biochehemistry and department of Pharmacology Faculty of Medicine and Health Sciences, UAE University during the years 2004-2007. My sincere thanks go to all of the people who contributed to this project: My PhD Thesis supervisors **Professor, Abdelrahim Osman Mohamed**, for guidance in the world of breast cancer genetics, for scientific conversations and encouragement and **Professor Abdu Adem** for insightful and constructive comments on my papers and for providing excellent research facilities. Special thanks to Prof Kamal Hamed, Prof. Mohamed Almaki Abedella Kartoum University Hospital, University of Khartoum, Sudan. The dean of the Faculty of Medical laboratoy Science, for giving me this oppertunity, Former dean Dr Abed Almuti Almahal all colleges at Sudan University of Science and Technology., Professor Sherif Karam Professor Tahir Resife, and **Dr. Omer Al Agnaf** , for Providing some of the research staff. All coauthors: **Dr Ahmed Almarzugi**, for helpfully welcoming me in his lab offering me with all consumable **Dr. Roos, Dr. Nico, Dr. Erica and Mr. Mohammed** for making this study go so smoothly also my thanks extend to the Sudanese staff in the faculty of medicine at the UAEU, for help and support prof Mohamed Al Sadsig, **Mr Hussien** and **Mr Hisham** for their help and support. **Dr. Emad FadilAlmula, Atif Alageb** and **Dr Abed Allah** for their help and support. **Dr Ebtisam** the molecular biologist, for her optimism and encouraging. Colleagues and coworkers, former and present, **Prof. Mohamed Abed alraheim** our guidance in Biochemistry **Dr. Khalda Mergani** and **Dr. Nawal**

Babiker, for great pieces of advice during of PhD project, **Dr. Samia. Dr. Hanan Eltahir** and **Dr. Hanan Babiker** for lifelong friendship and for stumbling along the pathway to the doctorate together and for sharing the ups and downs in life and science. Dear **Ammar, Wigdan** and **Ensaf** for great help during sample collection. My thank extend to **Miss. Salma**, who supported me more than one could ever ask and for companionship on trips to Dubai and Abu Dhabi, for attending occasions such like conferences and Seminars together. and for refreshing tea break, discussions of more or less scientific topics. for helping with all possible practical matters during these years, Suha and Meriam the young ladies for help and support. Members of the neuroscience group for exciting days that we share and for friendship,. My dear friends present and former **Dr. Manal** for being my “sister”; **Ms Soad** and **Dr. Soad, Dr. Nayla** for also for invaluable help and support during hard time that I experienced and for friendship extending beyond science. All friends and their families for numerous unforgettable moments and for putting up with me. My thanks to the young Sudanese ladies Samah. Fadowa Gada Somia and Reem as well as Mr Mohamed and Mr Abed Algader for their help and for creating such a nice work atmosphere, when being busy in the lab and while on a coffee break. Especial thank for UAE friends ladies **Ms Wafa, Amna, Nadia, Eman** and **Shiehka.**, Ebtisam and Mushfiga Indiaan friends especially **Dr. Shella Dr. Roni Dr. Roheini, Mr. Gurichi** and **Mr. Gaber, Ms. Anne and Seniha**. It has definitely been an extraordinary time.

My dear brother **Ahmed** , for being awanderfull brother offering me with great help and Support My family dearest husband balancing my life, his continuous enthusiasm, and support during these years. My son Saddain the trouble maker, my dearest sisters and my brothers, my sisters in law and brothers in law, all lovely

neices and nephews, for always loving me, encouraging me, believing in me. All of the patients, who by volunteering to participate, made this study possible.

Table of Contents:

Contents	Page No.
Dedication.....	i
Acknowledgment.....	ii
List of contents	iv
List of tables	vi
List of figures	vii
Abbreviations.....	viii
Abstract.....	ix
Arabic Abstract	xi
1-Introduction & Literature Review.....	1
1.1Oncogenes	3
1.2 Tumor suppressor genes	3
1.3 Loss of Heterozygosity.....	4
1.4 Epidemiology of breast cancer.....	6
1. 5 Clinicopathologic features of breast cancer.....	7
1.6 Risk factors	8
1.7 Genetic predisposition.....	11
1.7.1 High penetrance genes and hereditary breast cancer.....	11
1.7.2 Low penetrance genes and sporadic breast cancer.....	11
1.7.2.1 Single Nucleotide polymorphism (SNP).....	12
1.7.2.2 Importance of the polymorphisms	15
1.7.2 .3 Haplotyping	15
1.8 Breast Cancer-associated mutations in ESR1.....	16
1.8.1 Estrogen and Estrogen Receptor	16
1.8.2 ESR1 Alteration in Breast cancer.....	20
1.8.3 ESR1 somatic mutations in tumors.....	21
1.9 Breast Cancer-associated mutations in HER-2/neu gene	23
1.9.1 HER2	23
1.9.2. HER-2/neu gene polymorphism in Breast cancer	24
1.10 Breast Cancer-associated mutations in P53BP1 gene	25
1.10.1 P53BP1	25
1.10.2 P53BP1 gene polymorphism in Breast cancer.....	27
2. Aims of study	27
3. Patients and Methods.....	28
3.1 Study population:	28
3.2 Sampling.....	28
3.3 DNA extraction.....	28
3.4 Genotyping methods.....	29
3.4.1 PCR-SSCP Genotyping.....	29
3. 4.1.1 SSCP Procedure	30
3. 4.1.2 SSCP Limitation and consideration	31

3.4.2 PCR-RFLP genotyping:	32
3.4.2.1 Source:	32
3.4.2.2 Reagents Supplied.....	32
3.4.2.3 Enzyme Properties.....	32
3.4.2.4 Heat Inactivation:	32
3.3.2.5 Survival in a Reaction:	32
3.4.2.6 Reaction and Storage Conditions.....	32
3.4.2.7 Reaction Conditions.....	32
3.4.2.8. Unit Definition.....	33
3.4.2.9 Concentration.....	33
3.4.2.10 Storage Conditions.....	33
3.4.2.11 Storage Temperature.....	33
3.4.2.12 Hours of Incubation.....	33
3.4.3 Genotyping by Real Time PCR.....	34
3.4.3.1 Allelic discrimination with fluorogenic probe hybridization.....	35
3.4.3.1.1 (TaqMan) assay	35
3.5 Statistical Analysis	38
3.6 Informed Consent	
39	
4. Results.....	40
4.1 Detection of the ESR1 C353G polymorphism by PCR-SSCP and PCR-RFLP....	40
4.2 Detection of the ESR1 C353G polymorphism by Real Time PCR.....	44
4.3 Detection of the HER-2/neu Ile655Val polymorphism By Real Time PCR.....	51
4.4 Combined effect of ESR1C325G and HER-2/neu Ile655Val.....	56
4.5 Detection of P53BP1 Glu353Asp and Gly412Ser.....	58
4.6 P53BP1 Glu535 Asp Gly 412Ser Haplotypes.....	59
5. DISCUSSION.....	71
5.1 General considerations of the study design.....	71
5.2.Genetic polymorphisms and overall breast cancer risk	72
5.3 ESR1 C325G polymorphism and risk of breast cancer.....	72
5.4 HER-2/neu Ile655Val polymorphism and risk of breast cancer.....	74
5.5 Joint Effect of ESR1C325G and HER-2/neu Ile655Val and risk of breast cancer..	75
5.6 P53BP1Glu353Asp and Gly412Ser polymorphisms and risk of breast cancer.....	76
5.7 Genetic polymorphisms and breast cancer risk in relation to age.....	77
5.8 Genetic polymorphisms and breast cancer risk in relation to endogenous hormones and parity.....	78
5.9 Genetic polymorphisms and breast cancer risk in relation to other risk factors.....	79
5.10 Somatic mutation and risk of breast cancer.....	80
5.11 General discussion.....	81
6. Concluding Remark	85
7. Future Direction.....	87
8. References	88

List of tables

Table No.	Title	Page No.
Table 1	Previously published studies about HER-2/neu Ile655Val polymorphism and risk of breast cancer	24
Table 2	Demographic and clinical characteristics of 100 patients with breast cancer and 90 controls..	41
Table 3	Genotypic and allelic frequencies of ESR1C325G in the Sudanese population.....	45
Table 3.1	Genotypic and allelic frequencies stratified by age.....	46
Table 3.2	Genotypic and allelic frequencies stratified by menopausal status.....	47
Table 3.3	Genotypic and allelic frequencies stratified by parity.....	48
Table 3.4	Comparison of the genotype of the tumor tissue to that of its matched normal adjacent tissue in 79 patients.....	49
Table 4	Genotypic and allelic frequencies of HER-2/neu Il655Val in the Sudanese population.....	52
Table 4.1	Genotypic and allelic frequencies stratified by age.....	53
Table 4.2	Genotypic and allelic frequencies stratified by menopausal status.....	54
Table 4.3	Comparison of the genotype of the tumor tissue to that of its matched normal adjacent tissue in 67 patients	55
Table 5	Stratified analyses between HER-2/neu polymorphisms and breast cancer risk by ESR1 genotypes	56
Table 6	Genotypic and allelic frequencies of P53BP1 Glu353Asp in the Sudanese population.....	60
Table 6.1	Genotypic and allelic frequencies of P53BP1 Glu353Asp stratified by age	61
Table 6.2	Genotypic and allelic frequencies of P53BP1 Glu353Asp stratified by menopausal status....	62
Table 6.3	Comparison of the genotype of the tumor tissue of Glu353Asp to that of its matched normal adjacent tissue	63
Table 7	Genotypic and allelic frequencies of P53BP1 Gly412Ser in the Sudanese population.....	65
Table 7.1	Genotypic and allelic frequencies of P53BP1 Gly412Ser stratified by age.....	66
Table 7.2	Genotypic and allelic frequencies of P53PB1Gly412Ser stratified by menopausal status.....	67
Table 7.3	Comparison of the genotype of the tumor tissue of Gly 412 Ser to that of its matched normal adjacent tissue	68
Table 8	Distribution of different haplotypes of P53BP1 Glu 353Asp and Gly 412 Ser.....	70

List of Figures

Figure No.	Title	Page No.
Figure1	Nucleotide Changes	14
Figure 2	Model of estrogen action.....	18
Figure 3	Principle of allelic discrimination assay.	37
Figure 4	Vriation in clustring of alleles due to the differences in the extent of PCR amplificatin,	37
Figure 5	Representative banding pattern in malignant DNA band (M) and their counterpart normal adjacent DNA.....	42
Figure 6	Representative banding pattern in malignant blood DNA band (Mb) and the controls DNA (C).	42
Figure 7	Representative electrophotogram of ESR1 Hinf1 endonuclease digestion	43
Figure 8	Genotype frequency of C325G in patients and controls.....	50
Figure 9	Genotypic frequency of Ile655Val in cases and controls.....	57
Figure10	Genotypic frequency of Glu353Asp in cases and controls.....	64
Figure11	Genotypic frequency of Gly 412 Ser in cases and controls.....	69

Abbreviations

ESR1	Estrogen receptor α gene
HER-2/neu	Epidermal growth factor receptor gene
P53BP1	P53 binding protein 1 gene
AP1	Amplified protein 1
AIB1	Amplified in breast cancer gene1
RGS	regulators of G protein signaling
SERM	Selective estrogen receptor modulator
ERKO	Estrogen receptor knockout mice
MGB	minor groove binder
aa	amino acid(s)
Ile	Isoleucine
Val	valine
Glu	Glutamate
Asp	Aspartate
Gly	Glycine
Ser	Serine
CI	confidence interval
DNA	deoxyribonucleic acid
ER	estrogen receptor
LOH	loss of heterozygosity
HRT	Hormone replacement therapy
OR	odds ratio
p	short arm of a chromosome
q	long arm of a chromosome
PCR	polymerase chain reaction
PR	progesterone receptor
RFLP	restriction fragment length polymorphism
SNP	single nucleotide polymorphism
SSCP	single-strand conformation polymorphism
UTR	untranslated region
wt	wild-type

Abstract

Breast cancer, is a common type of cancer, with over two million newly diagnosed cases annually worldwide. In Sudan breast cancer is the most common cancer comprising 34% of all cancer patients. The functionally defective mutations in BRCA1 and BRCA2 genes are responsible for up to 5% of all breast cancer patients, while other genes (so-called low penetrance genes) account for the remainder of breast cancer patients. Among those possible low penetrance candidate genes for breast cancer are, ESR1, HER-2/neu and P53BP1 genes. Since single-nucleotide polymorphism (SNP) is the most frequent and most subtle genetic variation in the human genome and has great potential for application to association studies of complex diseases such as that of breast cancer the aim of this study was to evaluate the role of ESR1, HER-2/neu and P53BP1 polymorphisms in breast cancer predisposition in Sudanese breast cancer patients and in breast cancer risk at the population level.

This is a case control study where we genotyped a total of 81 breast cancer patients and 91 age matched healthy controls for 4 SNPs, namely, ESR1 variant C325G [db SNP rs1801132] and HER-2/neu codon 665 Ile –Val polymorphism [db SNP rs1136200] as well as 2 SNPs in P53BP1 tumor suppresser gene namely Glu 353 Asp or 1236C→G [db SNP rs560191] and Gly 412 Ser [db SNPrs689647]

The role of these polymorphism in breast cancer susceptibility were investigated using both conventional genotyping technique and high throughput Tag Man allelic discrimination method (SNP scoring methods) using Real-Time PCR technique . Data on clinical features and demographic details were collected. The association between the case –control status and each individual SNP, measured by the odds ratio and its corresponding 95% confidence interval, was estimated using unconditional logistic

regression models. At the second stage, two-way interactions were investigated using multivariate logistic models. The C allele of ESR1 codon C325G was shown to exhibit significant association of breast cancer risk in the subgroup of women 50 years and younger in the patients group compared to control subjects ($P= 0.03$) (OR: 2.28, 95%CI: 1.10-4.72). However, the overall susceptibility to breast cancer was not significant, although all estimates were in the direction of a higher risk in women with CC genotypes. Regarding the HER-2/neu codon 655Leu/Val variant we observed a modest positive association for Ile/Val versus Ile/Ile genotype in patients with breast cancer compared to control subjects (OR= 2.95, 95% CI 0.97-8.96), the Ile/Val heterozygous were more common among patients ($P= 0.06$). No associations of Val allele with breast cancer when stratified by menopausal status or age were observed. Genotypic and allelic frequencies of the P53BP1 Glu325Asp and of P53BP1 Gly412Ser lack association with respect to breast cancer risk when considered in overall, stratification according to menopausal status shows a modest increase of risk among homozygous carrier of P53BP1 412Ser/Ser $P=0.08$ (OR = 4.00, 95% CI 0.85-18.34) in post menopausal patients compared to postmenopausal control women and of Ser alleles carrier $P=0.05$ (OR= 5.71 (95% CI .0.92–5.5). No significant associations were seen among homozygous carrier of P53BP1 353 Asp/Asp neither of Glu alleles versus Asp alleles in the menopausal subgroup. In the haplotype of the 2 SNPs of P53BP1, no significant associations were observed. Nor when the genotype investigated in overall to the breast cancer risk. These results indicate that polymorphisms of these selected breast cancer susceptibility genes vary in their association with breast cancer. Genetic epidemiology study replication and functional assay of these SNPs as well as of haplotypes should permit a better understanding of the role of these genetic variants and breast cancer risk.

مستخلص البحث

يعد سرطان الثدي من أكثر أنواع السرطانات شيوعاً، حيث يتم سنوياً تشخيص أكثر من مليوني حالة حول العالم. وفي السودان يعتبر سرطان الثدي من أكثر السرطانات تفشياً ويشكل حوالي 34% من العدد الكلي للمصابين بمرض السرطان. أثبتت الدراسات أن وجود خلل في الجينات المعروفة بـ (BRCA₁ BRCA₂) يمثل إحدى العوامل في الإصابة بالمرض في حوالي 5% من المرضى، بينما الجينات التي تعرف بـ (low penetrance genes)، تشكل النسبة المتبقية بالإصابة بمرض سرطان الثدي. أثبتت الدراسات السابقة وجود علاقة بالإصابة بمرض السرطان والتباين في جينات مستقبلات الاستروجين ألفا ESR1، جينات مساعداً النمو الأيديرمية HER-2 والجينات المثبطة للنمو P53PBI وتعتبر من العوامل التي تجعل الفرد أكثر قابلية للإصابة بمرض سرطانات الثدي.

تهدف هذه الدراسة الي تقويم دور تباين الجينات في القابلية بالإصابة بسرطان الثدي في السودان. شملت الدراسة تبييط 4 متغيرات variants في 3 جينات في عدد 81 حالة سرطان ثدي و 91 أصحاء. فُحصت المتغيرات الجينية باستخدام التقنيات التقليدية علي سبيل المثال (RFLP و SSCP) بالإضافة الي استخدام تقنيات عالية المستوي علي سبيل المثال (Realtime PCR, Tag Man) باستخدام (allelic discrimination) كذلك تم جمع البيانات الإكلينيكية والديمغرافية وقد تم قياس العلاقة بين المتغيرات Variants الجينية في المصابين والأصحاء مستخدماً الطريقة الاحصائية التي تعرف Chi Square.

وقد توصلت الدراسة الي النتائج التالية :

1. إن المتغير Variant C في جين ESRI يوضح فروقات معنوية في مجموعة من النساء اللاتي تقل أعمارهن عن 50 عاماً بمقارنة المجموعة المماثلة من الأصحاء (OR: 2.28, 95%CI: 1.10-4.72) (P= 0.03)، بينما لا توجد فروقات ذات دلالة معنوية عند دراسة المجموعة ككل.
2. لوحظ وجود علاقة ايجابية (P= 0.06) بين حاملي المتغير ILe/Val.Variant في المرضى مقارنة بالأصحاء (OR= 2.95, 95% CI 0.97-8.96).
3. لا توجد فروقات ذات دلالة معنوية لحاملي المتغير Variant عندما قُسمت المجموعات علي أساس سن اليأس والعمر) < و > عاماً).
4. لا توجد فروقات ذات دلالة معنوية في متغيرات Variants جينات P53BP1 Glu325Asp and P53BP1 Gly412Ser عند دراسة المجموعة ككل في مجملها. عندما درست هذه المتغيرات Variants الأنفة الذكر علي أساس فيما بعد سن اليأس (menopausal status) وجدت فروقات معنوية لحاملي المتغير Ser (P=0.05 (OR= 5.71 (95% CI .0.92-5.5).

خلصت هذه الدراسة الي ان المتغيرات Variants في هذه الجينات المذكورة تتفاوت في درجة علاقتها بالإصابة بمرض سرطان الثدي. إجراء المزيد من الدراسات في الدور الوظيفي لهذه المتغيرات Variants للوصول الي فهم دقيق لمخاطر سرطان الثدي.